Engineered to give you confidence and control over your respiratory clinical study

Asthma trials depend on daily ePRO symptom diaries and peak flow logging to establish baseline severity and capture primary endpoints. Exacerbation events: clinically significant moments the trial most needs to capture,  are also when patients are most symptomatic, fatigued, and least able to log consistently, directly compromising efficacy signal integrity.

Rapid penetration of approved biologics has depleted the treatment-naive pools that trials historically relied on. Washout from partially effective therapies triggers exacerbation rebounds patients refuse to risk. Screen failure rates climb as sites exhaust databases, and enrollment extends into markets with lower biologic access that may not reflect your target population.

Patients experiencing acute exacerbations during the trial are at greatest risk of dropout: either hospitalized and removed from the outpatient protocol, or discharged and disengaged before completing follow-up. This creates systematic data gaps at the most clinically important timepoints, and the remaining cohort trends toward milder phenotypes that compress the apparent treatment effect.

COPD exacerbations present across emergency departments, primary care, and pulmonology: rarely at trial sites. Patients receive rescue courses in non-study settings without site notification, introducing unreported concomitant medications and missing efficacy event documentation. Standard monitoring visits are too infrequent to detect these episodes, leaving critical endpoint data uncaptured.

COPD trials depend on spirometry for eligibility and primary endpoints, but technique-sensitive measurements are highly operator-dependent. Variability in technician training and equipment calibration across a distributed site network generates inconsistent baseline values, inflated screen failure rates, and endpoint noise requiring expanded sample sizes to accommodate.

COPD patients typically present with cardiovascular disease, metabolic syndrome, and anxiety generating concomitant medication use that conflicts with protocol restrictions. Undisclosed rescue medications, dose adjustments, and intercurrent hospitalizations accumulate silently between monitoring visits, compromising safety and efficacy analyses at database lock.

Active CPAP users must withdraw from therapy to establish a baseline, but returning oxygen desaturation creates drowsy-driving risk and discomfort that drives consent refusals and pre-randomization dropout. Scheduling multiple overnight polysomnograms around constrained sleep lab availability extends screening timelines and creates bottlenecks stalling enrollment velocity.

Women and patients with comorbid insomnia frequently present with fatigue, cognitive symptoms, and sleep fragmentation rather than classic daytime sleepiness. Standard questionnaires miss these patients, routing them to psychiatry or primary care. Reliance on sleep clinic referral networks skews enrolled populations toward classic male phenotypes and limits demographic diversity.

Minimally symptomatic OSA patients lack the intrinsic motivation that symptom relief provides. When repeated overnight polysomnograms require travel and sleep disruption, patients who feel subjectively well view continued participation as purely burdensome. Progressive loss-to-follow-up leaves primary endpoint datasets incomplete and erodes statistical power.

Excluding active NTM infections requires slow-growing sputum cultures with multi-week turnaround. During this holding period, patients with high exacerbation burden may experience acute flares requiring rescue antibiotics: triggering baseline instability violations and screen failures after significant investment. The resulting bottleneck forces sponsors to activate larger site footprints to absorb the yield loss.

Active microbiological confirmation is required alongside an exacerbation-free stability window: but when patients are stable, bacterial loads frequently fall below detection. Active pathogen presence often signals an acute flare that disqualifies on stability criteria. This paradox forces multiple re-screening attempts consuming coordinator bandwidth without producing randomized participants.

Daily sputum quantification logging adds administrative burden to patients already managing intensive airway clearance regimens. The psychological weight of tracking purulent output combined with complex dosing schedules drives diary fatigue and covert non-adherence. Missing entries compromise exacerbation endpoint evaluability in exactly the patients most representative of your target population.

Chronic cough patients cycle across primary care, ENT, gastroenterology, and pulmonology depending on dominant symptoms. No single specialty owns the diagnosis, traditional investigator databases yield sparse pre-screening pools, and coordinators must build cross-disciplinary referral pathways to intercept patients still within a treatable window.

Continuous acoustic monitoring requires 24-hour audio recording that generates high consent refusal rates. Natural cough variability and at-home device errors produce unreadable data requiring repeat monitoring periods. Centralized over-read introduces lag that extends screening timelines, and specialized infrastructure requirements limit your viable site pool.

ACE inhibitor-induced cough requires washout coordination with primary care or cardiology before patients can qualify. Patients hesitate to alter functioning cardiac regimens, and multi-specialty coordination extends screening timelines. Incomplete documentation of medication switches risks protocol deviations and introduces noise into safety and efficacy data.

Influenza trials require laboratory confirmation within narrow symptom-onset timeframes, but patients delay care until symptoms escalate. By the time central lab results confirm eligibility, many candidates have aged out of the protocol window. Sites screen large volumes only to exclude patients on elapsed timing: stalling enrollment during unpredictable seasonal waves.

Elderly patients present with delirium, falls, or cardiovascular events rather than classic respiratory symptoms. Viral etiology is recognized only after standard workup: by which time the eligibility window has often closed. Proxy consent requirements add administrative delay in settings already compressed by acute clinical demands.

Protocols mandate compressed early visit schedules for PK sampling and viral swabbing precisely when patients are most symptomatic, contagious, and physically unable to travel repeatedly. High rates of missed visits and attrition follow. Conducting invasive procedures during peak viral shedding requires isolated infrastructure that limits the pool of capable sites.

Infants typically arrive at the emergency department days after upper respiratory onset, once lower airway involvement emerges. By this point viral load has peaked, rendering them ineligible for early-intervention protocols. Identifying candidates requires reaching families before the acute ED presentation: a structural gap that traditional site-based recruitment cannot bridge.

Enrolling infants with respiratory distress requires complex consent discussions in acute care settings where caregivers are managing an immediate clinical crisis. The prospect of experimental participation compounds parental distress, generating high refusal rates and systematically skewing enrolled populations away from the most acute phenotypes the trial is designed to study.

In immunocompetent adults, RSV resolves rapidly. Once acute symptoms subside, participants resume normal routines and perceive ongoing longitudinal swabbing and diary requirements as unnecessary burdens. Progressive loss-to-follow-up leaves secondary endpoint datasets incomplete and the effort to re-engage unmotivated participants consumes monitoring resources without reliably recovering evaluable data.